149 related articles for article (PubMed ID: 17405890)
1. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
Colozza M; de Azambuja E; Personeni N; Lebrun F; Piccart MJ; Cardoso F
Oncologist; 2007 Mar; 12(3):253-70. PubMed ID: 17405890
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Colozza M; de Azambuja E; Cardoso F; Bernard C; Piccart MJ
Oncologist; 2006 Feb; 11(2):111-25. PubMed ID: 16476832
[TBL] [Abstract][Full Text] [Related]
3. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
6. The choice of systemic adjuvant therapy in receptor-positive early breast cancer.
Dellapasqua S; Castiglione-Gertsch M
Eur J Cancer; 2005 Feb; 41(3):357-64. PubMed ID: 15691634
[TBL] [Abstract][Full Text] [Related]
7. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M
Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963
[TBL] [Abstract][Full Text] [Related]
8. Endocrine management of breast cancer.
Schneider PG; Jackisch C; Brandt B
Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
[TBL] [Abstract][Full Text] [Related]
9. Progress in systemic adjuvant therapy of early-stage breast cancer.
Gradishar WJ; O'Regan RM
Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the treatment of metastatic breast cancer.
Gralow JR
Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
[TBL] [Abstract][Full Text] [Related]
12. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
13. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
14. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
15. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
[TBL] [Abstract][Full Text] [Related]
16. Update on endocrine therapy for breast cancer.
Buzdar AU; Hortobagyi G
Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
[TBL] [Abstract][Full Text] [Related]
17. First-line chemotherapy for metastatic breast cancer.
Telli ML; Carlson RW
Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
[TBL] [Abstract][Full Text] [Related]
18. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.
Munzone E; Curigliano G; Rocca A; Bonizzi G; Renne G; Goldhirsch A; Nolè F
Breast Cancer Res; 2006; 8(1):R4. PubMed ID: 16417653
[TBL] [Abstract][Full Text] [Related]
19. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
[TBL] [Abstract][Full Text] [Related]
20. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
